Solid Biosciences signed a gene therapy agreement with CDMO Andelyn Biosciences for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101. Solid grants Andelyn a non-exclusive worldwide license to provide its gene therapy clients with access to utilize AAV-SLB101 in combination with Andelyn’s suspension and adherent modular platform process, the AAV Curator® platform, which Solid officials say brings a modular approach to gene therapy CMC processes by optimizing manufacturing and using configurable materials. Specific financial terms of the agreement have not been disclosed.
AAV-SLB101 is Solid’s rationally designed capsid developed for enhanced skeletal muscle and cardiac tropism and reduced biodistribution to the liver. As of the recently reported safety cutoff of October 31, 2025, AAV-SLB101 has been generally well tolerated in the 23 pediatric participants who have been dosed in Solid’s Phase I/II INSPIRE DUCHENNE clinical trial (NCT06138639) evaluating investigational Duchenne muscular dystrophy gene therapy SGT-003, which utilizes AAV-SLB101.
Preclinical and early clinical data
Robust cardiac and skeletal muscle transduction and biodistribution have been demonstrated in preclinical studies as well as in early clinical data from INSPIRE DUCHENNE.
“We are excited to announce a new non-exclusive license for AAV-SLB101 with Andelyn Biosciences,” says Bo Cumbo, president and CEO of Solid Biosciences. “This collaboration reflects our shared mission to accelerate the next generation of gene therapies built upon cutting-edge technologies designed to enhance safety and efficacy.
“With more than 30 agreements and licenses already in place for the use of AAV-SLB101, we expect our partnership with Andelyn to help trailblaze a brighter future for gene therapy. Their pioneering and configurable CDMO model will broaden access to our proprietary capsid, enabling early-stage gene therapy programs to harness next-generation technology and benefit from the differentiated profile of AAV-SLB101.”
According to Matt Niloff, COO of Andelyn, “We are eager to provide our clients with access to Solid’s novel capsid, AAV-SLB101. By integrating this next-generation technology into our AAV Curator, we can offer an advanced gene therapy vector that has been clinically validated and ultimately may allow for faster and more cost-effective development.”
